Silver nanoparticles enhance the sensitivity of temozolomide on human glioma cells

• Published in: Oncotarget 2017-01, Vol.8 (5), p.7533-7539
• Main Authors: Liang, Ping, Shi, Hongming, Zhu, Weiguo, Gui, Qunfeng, Xu, Ya, Meng, Jianfeng, Guo, Xiaoyuan, Gong, Zhuang, Chen, Huaqun
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents, Alkylating - pharmacology; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Apoptosis - drug effects; Brain Neoplasms - drug therapy; Brain Neoplasms - pathology; Cell Line, Tumor; Cell Proliferation - drug effects; Dacarbazine - analogs & derivatives; Dacarbazine - pharmacology; Dose-Response Relationship, Drug; G2 Phase Cell Cycle Checkpoints - drug effects; Glioma - drug therapy; Glioma - pathology; Humans; Metal Nanoparticles; Research Paper; Silver Compounds - pharmacology
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.13503

Glioblastoma multiforme (GBM) continues to be associated with a dismal prognosis despite aggressive treatment. Significant efforts are being made to develop new nanotechnology-based therapeutic and diagnostic agents. Nanoparticles can act directly on cancer cells or as drug carriers to enhance the cancer therapeutic effect. In this study, we investigated the effect of silver nanoparticles (AgNPs) on human glioma U251 cells and its role in the combinational use with Temozolomide (TMZ), an imidazotetrazine derivative of the alkylating agent dacarbazine, against glioma cells. AgNPs were synthesized in the sodium citrate system and the mean size were 26 nm in diameter. The AgNP particles showed dose-dependent cytotoxicity on U251 cells. They also showed the ability to enhance the drug-sensitivity of TMZ on U251 cells. Our results revealed that AgNPs could have a potential application in enhancing chemotherapy for glioma.